Skip to content
  • Intrommune is supported by the Allergy & Asthma Network
  • More Information
  • Intrommune is supported by the Allergy & Asthma Network
  • More Information
Intrommune TherapeuticsIntrommune Therapeutics
  • About Us
    • Overview
    • Company Leadership
  • Intrommune R&D
    • Food Allergies
    • Oral Mucosal Immunotherapy
    • INT301 for Peanut Allergy
  • Media
    • Press Releases
    • Events
    • Intrommune in the News
  • Investors
    • Videos
  • White Paper
  • Contact Us
  • Newsletter

    Sign up for Intrommune's newsletter and stay informed of company developments.

    Intrommune in the News

    March 2021

    Drug Development & Delivery: Oral Mucosal Delivery of Allergenic Proteins for Inducing Tolerance in Food Allergic Individuals

    March 2021

    Daily Mail: Peanut Allergies Could Get The Brush Off In Toothpaste Trial

    March 2021

    Intrommune Therapeutics selected as a “Winning Startup” in The Innovate Children’s Health Challenge (ICHC)

    List of Challenge Winners

    March 2021

    Interesting Engineering: Experimental Toothpaste Might Treat Peanut Allergy

    March 2021

    Nerdist: A New Toothpaste May Help Treat Peanut Allergies

    March 2021

    Science News: An experimental toothpaste aims to treat peanut allergy

    February 2021

    Chief Science Officer Erick Berglund interviewed on the Price of Business with Kevin Price

    February 2021

    Global Data publishes profile of Intrommune Therapeutics’ Phase Ib study and its Series B raise

    January 2021

    Intrommune presentation at the H.C. Wainwright BioConnect 2021 Conference by Dr. Abhit Singh

    December 2020

    William Reisacher, MD’s article in Coping with Allergies & Asthma: Five Things you Should Know about Peanut Allergy Immunotherapy

    November 2020

    Intrommune CEO, Michael Nelson, spoke with PetaCrunch about Intrommune’s approach to treating peanut allergies

    October 2020

    Intrommune selected as Semifinalist in the Innovate Children’s Health Challenge

    March 2020

    Senior Medical Advisor, William Reisacher, interviewed on the Price of Business with Kevin Price

    January 2020

    Proactive Interview: Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process

    September 2019

    Providing Innovative Treatments for Peanut Allergies
    Intrommune CEO, Michael Nelson, interview on the Price of Business with Kevin Price

    September 2019

    Science News: Liquid mouth drops could one day protect people from peanut allergies

    Octoberber 2018

    Intrommune Therapeutics selected as one of the RESI NYC Innovation Challenge Finalists

    July 2018

    Intrommune Senior Scientific Advisor, Dr. Reisacher, featured in SELF article: Southwest Airlines Is Finally Getting Rid of In-Flight Peanuts

    June 2018

    Q&A with Michael Nelson, JD, Co-Founder and CEO of Intrommune Therapeutics
    developing a revolutionary new Drug Delivery method using Toothpaste to
    Deliver an Oral Mucosal Immunotherapy for People who have a Peanut Allergy

    May 2018

    New Idea for Immunotherapy–an Interview with Dr. Toothpaste

    Copyright 2021 © Intrommune Therapeutics. All Rights Reserved.

    Privacy Policy

    • About Us
      • Overview
      • Company Leadership
    • Intrommune R&D
      • Food Allergies
      • Oral Mucosal Immunotherapy
      • INT301 for Peanut Allergy
    • Media
      • Press Releases
      • Events
      • Intrommune in the News
    • Investors
      • Videos
    • White Paper
    • Contact Us
    • Intrommune is supported by the Allergy & Asthma Network
    • More Information

    Login

    Lost your password?